SLC6A3 and obesity due to melanocortin 4 receptor deficiency: Dopamine transporter remains a potential target for antagonist or antagonist-like substitution therapies for stimulant abuse as well as obesity (Schmitt and Reith, 2010; Reith et al., 2015).